Comparing two maintenance therapies after stem cell transplant for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests two treatments (lenalidomide plus elranatamab versus lenalidomide plus daratumumab) as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see which combination is better at keeping the cancer in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma and have received 4 to 6 cycles of a combination therapy that includes a proteasome inhibitor, an IMiD, and an anti-CD38 antibody.
- You must have had a stem cell transplant (ASCT) within the past 6 months, and you must have achieved at least a partial response to your initial therapy.
- You have not had any prior maintenance therapy after transplant, and you have not been treated with a BCMA-targeted therapy.
- Your kidney, liver, and blood counts must be within acceptable ranges (e.g., creatinine clearance of at least 30 mL/min, hemoglobin above 8 g/dL).
- You are not pregnant, and if you or your partner can have children, you agree to use highly effective contraception during and for 6 months after treatment.
- You do not have serious heart, lung, or other medical conditions that could interfere with participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized approach to maintenance therapy for people with multiple myeloma who have already had a stem cell transplant. Your treatment plan may be adjusted based on how well your cancer responds and on certain risk factors, with the goal of keeping you in remission longer.
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
This trial tests combining two drugs, talquetamab and lenalidomide, as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests two different drug combinations for people newly diagnosed with multiple myeloma who are not getting a stem cell transplant right away. It compares one drug (elranatamab) to another (daratumumab), both given with a standard three-drug regimen called RVd Lite, to see which works better.
This trial tests a drug called elranatamab to keep multiple myeloma from coming back after an autologous stem cell transplant. It is for people who still have small amounts of cancer cells detectable after transplant.
This trial tests two medicines, iberdomide and daratumumab, given as maintenance therapy after an autologous stem cell transplant. It is for people with multiple myeloma who still have small amounts of cancer cells detected after transplant and who have already been treated with a daratumumab-containing regimen.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.